TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06519565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRG-1801
Description: PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
Study: NCT06026813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test pressure alternating shoes
Description: test pressure alternating shoes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test pressure alternating shoes
Description: test pressure alternating shoes
Study: NCT05321563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)
Description: iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
Study: NCT06141512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high-intensity interval training (REHIT)
Description: Description same as Arm description.
Study: NCT05951907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary extraction without palatal injection
Description: Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary extraction with buccal and palatal injection
Description: Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
Study: NCT06565273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBL-MTX
Description: Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
Study: NCT06505226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in person meditation
Description: in person guided meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in person meditation using headphones
Description: in person meditation using headphones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual meditation
Description: virtually guided meditation via Zoom
Study: NCT06375681

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual and / or Auditory Cognitive Tasks (1)
Description: Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual and / or Auditory Cognitive Tasks (1)
Description: Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual and / or Auditory Cognitive Tasks (2)
Description: Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements.
Study: NCT04826380

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trapeziectomy
Description: Simple trapeziectomy (without LRTI)
Study: NCT06133023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic stent
Description: EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAMS
Description: EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed.
Study: NCT05547672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroMems artificial urinary sphincter
Description: Implantation of the device
Study: NCT05434234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Study: NCT05486767

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
Study: NCT06544720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG142 TCR-T cells
Description: Monotherapy of SCG142
Study: NCT04637945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACRB
Description: Product will be consumed once daily, preferably with breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product will be consumed once daily, preferably with breakfast.
Study: NCT06026865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S-Adenosyl-L-methionine (SAMe)
Description: S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of identical appearance, smell and taste, with the same schedule.
Study: NCT05322031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
Study: NCT05098392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sibling-mediated intervention
Description: Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
Study: NCT03971084

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar free gum without CPP-ACP
Description: Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar free gum with CPP-ACP
Description: Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Study: NCT05293652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Hydrocortisone iontophoresis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Hydrocortisone Phonophoresis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional PT program
Description: Ultrasound and deep friction massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional PT program
Description: Ultrasound and deep friction massage
Study: NCT06118658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
Study: NCT05293652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional PT program
Description: Ultrasound and deep friction massage
Study: NCT05408312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 1
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Study: NCT05539651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: Subcutaneously Administered RBD5044 in Healthy Subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: Subcutaneously Administered RBD5044 in Healthy Subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthy Subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthy Subjects
Study: NCT06297876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Learn More (Active Comparator)
Description: Informational videos that are of similar length and on the same topic as the storytelling videos.
Study: NCT04662164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients
Study: NCT05222685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching
Description: Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
Study: NCT04887675

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
Study: NCT04692909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS with mPFC stimulation
Description: dTMS with Brainsway's H7 device, stimulating the mPFC.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dTMS with mPFC stimulation
Description: dTMS with Brainsway's H7 device, stimulating the mPFC.
Study: NCT05408312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 2
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 3
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
Study: NCT05441514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study: NCT05759780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the tissues
Description: OCT vibrography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the tissues
Description: OCT vibrography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the tissues
Description: OCT vibrography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the tissues
Description: OCT vibrography
Study: NCT06564584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-2716 Dose 1
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-2716 Dose 2
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study: NCT05233839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Application based video home exercise for the degenerative meniscus injury

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Based Rehabilitation
Description: Paper instruction based home exercise for the degenerative meniscus injury
Study: NCT06009302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided block of mandibular nerve
Description: Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoral block of lower alveolar nerve
Description: Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
Study: NCT05170971

Intervention type: OTHER
Group type: OTHER
Intervention: fecal microbiota transplantation
Description: The fecal bacteria were transplanted once every 5 days for a total of 4 times
Study: NCT04858581

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Virological and serological tests
Description: Survey, RT-PCR test and blood test
Study: NCT05453461

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of new COMs for non ambulant FSHD patients
Description: Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
Study: NCT04655157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study: NCT05785208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered at a dose of 80 mg daily until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered at a dose of 80 mg daily until disease progression
Study: NCT04158089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)
Description: Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.).
Study: NCT05059886

Intervention type: OTHER
Intervention: completion of a questionnaire on the practice of sports and possible injuries
Description: completion of a questionnaire on the practice of sports and possible injuries
Study: NCT05270525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Ensifentrine twice daily administered with jet nebulizer for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Ensifentrine twice daily administered with jet nebulizer for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
Study: NCT05874726

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood collection via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood collection via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood collection via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Collection
Description: Free catch urine sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Collection
Description: Free catch urine sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Collection
Description: Free catch urine sample collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue Sample Collection
Description: Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue Sample Collection
Description: Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
Study: NCT06484504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kombucha beverage
Description: After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits